KYMR – kymera therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Form 4 Kymera Therapeutics, For: Dec 10 Filed by: Booth Bruce
Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Form SCHEDULE 13D/A Kymera Therapeutics, Filed by: BAKER BROS. ADVISORS LP
Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.